

Mitchel A Kling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3464268/publications.pdf>

Version: 2024-02-01

88
papers

8,114
citations

76326

40
h-index

62596

80
g-index

99
all docs

99
docs citations

99
times ranked

7790
citing authors

#	ARTICLE	IF	CITATIONS
1	732 A daily diary study of nightmare reports among combat-exposed Veterans. <i>Sleep</i> , 2021, 44, A286-A286.	1.1	0
2	The effect of plasmalogen precursor supplementation on blood catalase and malondialdehyde levels in cognitively impaired persons. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
3	Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. <i>Cell Reports Medicine</i> , 2020, 1, 100138.	6.5	102
4	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. <i>Alzheimer's and Dementia</i> , 2020, 16, 1234-1247.	0.8	15
5	Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 563-578.	2.6	5
6	P3-069: CHOLESTEROL EFFLUX CAPACITY (CEC) IN PLASMA AND CEREBROSPINAL FLUID (CSF) OF PATIENTS WITH ALZHEIMER'S DISEASE (AD) AND MILD COGNITIVE IMPAIRMENT (MCI) AND COMPARISON SUBJECTS: EFFECTS OF GENDER AND DIAGNOSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1090.	0.8	1
7	P2-261: APOLIPOPROTEIN J/CLUSTERIN IS THE PRIMARY DETERMINANT OF THE CHOLESTEROL EFFLUX CAPACITY OF CEREBROSPINAL FLUID. <i>Alzheimer's and Dementia</i> , 2018, 14, P776.	0.8	0
8	F3-0204: SERUM INDICES OF ETHANOLAMINE PLASMOGENS AND PHOSPHATIDE METABOLISM IN THE COMBINED ADNI-1/GO/2 COHORT: DOES THE LIVER CONTRIBUTE TO AD RISK BY FAILING TO SUPPLY KEY LIPIDS TO THE BRAIN?. <i>Alzheimer's and Dementia</i> , 2018, 14, P998.	0.8	1
9	F3-0201: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P997.	0.8	0
10	Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 991-1003.	2.6	12
11	P3-157: Indices of Plasmalogen Biosynthesis in ADNI-1 Baseline Serum Samples: Association with Progression to Dementia in Subjects with Mild Cognitive Impairment. , 2016, 12, P879-P880.		1
12	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 27-34.	2.4	44
13	A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 377-379.	1.2	32
14	Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications. <i>Translational Psychiatry</i> , 2015, 5, e576-e576.	4.8	12
15	Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 339-348.	2.4	35
16	P4-237: WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT. , 2014, 10, P873-P874.		0
17	Central and Peripheral Norepinephrine Secretion in Major Depression is Activated, as Assessed by 24 hour CSF and Plasma Sampling. , 2014, , 154-155.		0
18	Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. <i>Acta Neuropathologica Communications</i> , 2013, 1, 28.	5.2	45

#	ARTICLE	IF	CITATIONS
19	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2013, 333, 9-12.	0.6	55
20	Vascular disease and dementias: Paradigm shifts to drive research in new directions. <i>Alzheimer's and Dementia</i> , 2013, 9, 76-92.	0.8	117
21	Alterations in metabolic pathways and networks in Alzheimer's disease. <i>Translational Psychiatry</i> , 2013, 3, e244-e244.	4.8	174
22	Insomnia in Alcohol Dependence: Predictors of Symptoms in a Sample of Veterans Referred from Primary Care. <i>American Journal on Addictions</i> , 2013, 22, 266-270.	1.4	21
23	Subjective Memory Complaints, Cognitive Performance, and Psychological Factors in Healthy Older Adults. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 776-783.	1.9	114
24	Plasma biomarkers of depressive symptoms in older adults. <i>Translational Psychiatry</i> , 2012, 2, e65-e65.	4.8	48
25	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. <i>Brain</i> , 2012, 135, 3749-3756.	7.6	228
26	Unmedicated, remitted patients with major depression have decreased serum immunoglobulin A. <i>Neuroscience Letters</i> , 2012, 520, 1-5.	2.1	21
27	Acute Hydrocortisone Treatment Increases Anxiety but Not Fear in Healthy Volunteers: A Fear-Potentiated Startle Study. <i>Biological Psychiatry</i> , 2011, 69, 549-555.	1.3	32
28	Rat brain and serum lithium concentrations after acute injections of lithium carbonate and orotate. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 30, 368-370.	2.4	17
29	Imaging of CNS Systems: Importance for Drug Development. , 2010, , 11-28.		0
30	11 β -Hydroxysteroid Dehydrogenases Are Regulated during the Pulmonary Granulomatous Response to the Mycobacterial Glycolipid Trehalose-6,6'-Dimycolate. <i>NeuroImmunoModulation</i> , 2009, 16, 147-154.	1.8	18
31	Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus?. <i>Depression and Anxiety</i> , 2009, 26, 641-649.	4.1	45
32	Elevated Cerebrospinal Fluid Lactate Concentrations in Patients with Bipolar Disorder and Schizophrenia: Implications for the Mitochondrial Dysfunction Hypothesis. <i>Biological Psychiatry</i> , 2009, 65, 489-494.	1.3	136
33	Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. <i>Journal of the Neurological Sciences</i> , 2008, 275, 106-112.	0.6	84
34	Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. <i>Psychiatry Research</i> , 2008, 157, 123-129.	3.3	14
35	CRH Haplotype as a Factor Influencing Cerebrospinal Fluid Levels of Corticotropin-Releasing Hormone, Hypothalamic-Pituitary-Adrenal Axis Activity, Temperament, and Alcohol Consumption in Rhesus Macaques. <i>Archives of General Psychiatry</i> , 2008, 65, 934.	12.3	63
36	Activation of blood coagulation in patients with major depressive disorder during euglycemic hyperinsulinemia. <i>Thrombosis Research</i> , 2007, 120, 517-521.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Sustained Low-Grade Pro-inflammatory State in Unmedicated, Remitted Women with Major Depressive Disorder as Evidenced by Elevated Serum Levels of the Acute Phase Proteins C-reactive Protein and Serum Amyloid A. <i>Biological Psychiatry</i> , 2007, 62, 309-313.	1.3	101
38	Acute Stress Potentiates Anxiety in Humans. <i>Biological Psychiatry</i> , 2007, 62, 1183-1186.	1.3	92
39	Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women. <i>Osteoporosis International</i> , 2007, 18, 315-322.	3.1	33
40	Number of risk genotypes is a risk factor for major depressive disorder: a case control study. <i>Behavioral and Brain Functions</i> , 2006, 2, 24.	3.3	32
41	Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. <i>Molecular Psychiatry</i> , 2005, 10, 976-977.	7.9	54
42	Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. <i>Hepatology</i> , 2005, 41, 88-96.	7.3	196
43	Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8303-8308.	7.1	90
44	Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2522-2530.	3.6	330
45	Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study. <i>Biological Psychiatry</i> , 2005, 58, 355-363.	1.3	345
46	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial. <i>Biological Psychiatry</i> , 2005, 58, 347-354.	1.3	542
47	A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2005, 58, 364-373.	1.3	319
48	VNS and depression: current status and future directions. <i>Expert Review of Medical Devices</i> , 2004, 1, 155-160.	2.8	14
49	Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 385-392.	5.4	268
50	Treatment Outcomes in Depression: Comparison of Remote Treatment Through Telepsychiatry to In-Person Treatment. <i>American Journal of Psychiatry</i> , 2004, 161, 1471-1476.	7.2	307
51	Simultaneous and Continuous 24-Hour Plasma and Cerebrospinal Fluid Leptin Measurements: Dissociation of Concentrations in Central and Peripheral Compartments. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 258-265.	3.6	32
52	Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders. <i>Molecular Psychiatry</i> , 2004, 9, 731-733.	7.9	27
53	Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. <i>Biological Psychiatry</i> , 2004, 56, 418-426.	1.3	103
54	Antithyroid Antibody-Linked Symptoms in Borderline Personality Disorder. <i>Endocrine</i> , 2003, 21, 153-158.	2.2	9

#	ARTICLE	IF	CITATIONS
55	A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. <i>Molecular Psychiatry</i> , 2002, 7, 942-947.	7.9	296
56	Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders. <i>Psychoneuroendocrinology</i> , 2000, 25, 593-606.	2.7	28
57	Prophylactic Treatment of Depression Induced by Interferon- α . <i>Psychosomatics</i> , 2000, 41, 439-441.	2.5	65
58	Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 325-330.	7.1	518
59	Antidepressant effects of nicotine in an animal model of depression. <i>Psychopharmacology</i> , 1999, 142, 193-199.	3.1	200
60	Reliability and Acceptability of Psychiatric Diagnosis Via Telecommunication and Audiovisual Technology. <i>Psychiatric Services</i> , 1998, 49, 1086-1088.	2.0	119
61	Cerebrospinal fluid total protein in patients with affective disorders. <i>Psychiatry Research</i> , 1995, 57, 259-266.	3.3	9
62	Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. <i>Arthritis and Rheumatism</i> , 1994, 37, 1583-1592.	6.7	464
63	CSF magnesium in affective disorder: Lack of correlation with clinical course of treatment. <i>Psychiatry Research</i> , 1994, 51, 139-146.	3.3	23
64	Glucocorticoid treatment increases the ability of CRH to induce seizures. <i>Neuroscience Letters</i> , 1994, 174, 113-116.	2.1	33
65	Glucocorticoid Receptor (GR)-Mediated Effects on Cocaine Kindling in Rats. <i>Annals of the New York Academy of Sciences</i> , 1994, 746, 400-402.	3.8	1
66	Facilitation of cocaine kindling by glucocorticoids in rats. <i>Brain Research</i> , 1993, 629, 163-166.	2.2	36
67	Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. <i>Biological Psychiatry</i> , 1993, 33, 636-641.	1.3	63
68	Effects of the Glucocorticoid Antagonist RU 486 on Pituitary-Adrenal Function in Patients with Anorexia nervosa and Healthy Volunteers: Enhancement of Plasma ACTH and Cortisol Secretion in Underweight Patients. <i>Neuroendocrinology</i> , 1993, 57, 1082-1091.	2.5	41
69	Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. <i>American Journal of Psychiatry</i> , 1993, 150, 656-657.	7.2	264
70	Cerebrospinal Fluid Immunoreactive Somatostatin Concentrations in Patients with Cushing's Disease and Major Depression: Relationship to Indices of Corticotropin-Releasing Hormone and Cortisol Secretion. <i>Neuroendocrinology</i> , 1993, 57, 79-88.	2.5	26
71	Quantitative Electroencephalographic Correlates of Steroid Administration in Man. <i>Neuropsychobiology</i> , 1993, 27, 224-230.	1.9	9
72	Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: Preliminary findings. <i>Biological Psychiatry</i> , 1992, 32, 1065-1077.	1.3	73

#	ARTICLE	IF	CITATIONS
73	Cortisol, thyroid hormone, and mood in atypical depression: A longitudinal case study. <i>Biological Psychiatry</i> , 1992, 31, 515-519.	1.3	13
74	Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects. <i>Psychopharmacology</i> , 1992, 108, 225-228.	3.1	6
75	Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. <i>Psychiatry Research</i> , 1991, 37, 25-34.	3.3	38
76	Clinical and biochemical aspects of depressive disorders: I. Introduction, classification, and research techniques. <i>Synapse</i> , 1991, 8, 185-211.	1.2	21
77	Cerebrospinal Fluid Immunoreactive Corticotropin-Releasing Hormone and Adrenocorticotropin Secretion in Cushing's Disease and Major Depression: Potential Clinical Implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 260-271.	3.6	154
78	<i>In Vitro</i> and <i>In Vivo</i> Effects of the Triazolobenzodiazepine Alprazolam on Hypothalamic Pituitary-Adrenal Function: Pharmacological and Clinical Implications*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1462-1471.	3.6	123
79	Corticotropin-Releasing Hormone: From Endocrinology to Psychobiology. <i>Hormone Research</i> , 1989, 31, 66-71.	1.8	34
80	Cocaine stimulates rat hypothalamic corticotropin-releasing hormone secretion in vitro. <i>Brain Research</i> , 1989, 505, 7-11.	2.2	86
81	Neuroactive Substances in Cerebrospinal Fluid.. <i>Annals of the New York Academy of Sciences</i> , 1988, 531, 15-28.	3.8	11
82	The Clinical Implications of Corticotropin-Releasing Hormone. <i>Advances in Experimental Medicine and Biology</i> , 1988, 245, 507-519.	1.6	14
83	Neuroendocrine effects of limbic activation by electrical, spontaneous, and pharmacological modes: Relevance to the pathophysiology of affective dysregulation in psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1987, 11, 459-481.	4.8	20
84	Intravenous procaine as a probe of limbic system activity in psychiatric patients and normal controls. <i>Biological Psychiatry</i> , 1987, 22, 1107-1126.	1.3	53
85	Responses to Corticotropin-Releasing Hormone in the Hypercortisolism of Depression and Cushing's Disease. <i>New England Journal of Medicine</i> , 1986, 314, 1329-1335.	27.0	762
86	Abnormal acth and cortisol responses to ovine corticotropin releasing factor in patients with primary affective disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1986, 10, 57-65.	4.8	37
87	Corticotropin releasing factor: Basic studies and clinical applications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1985, 9, 349-359.	4.8	21
88	Amphetamine withdrawal: Effects on threshold of intracranial reinforcement. <i>Psychopharmacology</i> , 1981, 73, 318-322.	3.1	56